We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

Sanofi (NASDAQ:SNY) Q4 2024 Earnings Call Transcript ... First, the impact of price cuts of Lantus in the U.S. in H1 for €1.1 billion. Second, the entire elimination of all factoring of ...

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

The Sanofi Global Health Unit plays an important ... First, the impact of price cuts of Lantus in the U.S. in H1 for €1.1 billion. Second, the entire elimination of all factoring of receivables ...

The company projects mid to high single-digit sales growth in 2025 at constant exchange rates, excluding hyperinflation effects, and low double-digit business EPS growth before foreign exchange and ...

Sanofi SNY reported fourth-quarter 2024 adjusted ... In Others, Toujeo recorded sales of €290 million, up 6.5% year over year. Lantus sales rose 63.4% to €439.0 million. SNY & AZN’s ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales ...

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.